Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
Publication type: Journal Article
Publication date: 2013-12-01
scimago Q2
wos Q2
SJR: 0.829
CiteScore: 4.9
Impact factor: 2.3
ISSN: 15255050, 15255069
PubMed ID:
24237632
Neurology
Neurology (clinical)
Behavioral Neuroscience
Abstract
Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in children with treatment-resistant epilepsy. The survey was presented to parents belonging to a Facebook group dedicated to sharing information about the use of cannabidiol-enriched cannabis to treat their child's seizures. Nineteen responses met the following inclusion criteria for the study: a diagnosis of epilepsy and current use of cannabidiol-enriched cannabis. Thirteen children had Dravet syndrome, four had Doose syndrome, and one each had Lennox-Gastaut syndrome and idiopathic epilepsy. The average number of antiepileptic drugs (AEDs) tried before using cannabidiol-enriched cannabis was 12. Sixteen (84%) of the 19 parents reported a reduction in their child's seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported a 25-60% seizure reduction. Other beneficial effects included increased alertness, better mood, and improved sleep. Side effects included drowsiness and fatigue. Our survey shows that parents are using cannabidiol-enriched cannabis as a treatment for their children with treatment-resistant epilepsy. Because of the increasing number of states that allow access to medical cannabis, its use will likely be a growing concern for the epilepsy community. Safety and tolerability data for cannabidiol-enriched cannabis use among children are not available. Objective measurements of a standardized preparation of pure cannabidiol are needed to determine whether it is safe, well tolerated, and efficacious at controlling seizures in this pediatric population with difficult-to-treat seizures.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
25
|
|
|
Epilepsy and Behavior
23 publications, 8.19%
|
|
|
Epilepsia
6 publications, 2.14%
|
|
|
Frontiers in Pharmacology
5 publications, 1.78%
|
|
|
Frontiers in Neurology
4 publications, 1.42%
|
|
|
New England Journal of Medicine
3 publications, 1.07%
|
|
|
Cannabis and Cannabinoid Research
3 publications, 1.07%
|
|
|
Journal of Child Neurology
3 publications, 1.07%
|
|
|
Experimental Neurology
3 publications, 1.07%
|
|
|
Pediatric Neurology
3 publications, 1.07%
|
|
|
Seizure : the journal of the British Epilepsy Association
3 publications, 1.07%
|
|
|
Journal of Paediatrics and Child Health
3 publications, 1.07%
|
|
|
Paediatrics and Child Health
3 publications, 1.07%
|
|
|
Journal of Pharmacology and Experimental Therapeutics
2 publications, 0.71%
|
|
|
AAP Grand Rounds
2 publications, 0.71%
|
|
|
Journal of Developmental and Behavioral Pediatrics
2 publications, 0.71%
|
|
|
CMAJ Open
2 publications, 0.71%
|
|
|
Frontiers in Behavioral Neuroscience
2 publications, 0.71%
|
|
|
International Journal of Molecular Sciences
2 publications, 0.71%
|
|
|
Paediatric Drugs
2 publications, 0.71%
|
|
|
Current Treatment Options in Neurology
2 publications, 0.71%
|
|
|
Molecular Neurobiology
2 publications, 0.71%
|
|
|
Neurotherapeutics
2 publications, 0.71%
|
|
|
CNS Drugs
2 publications, 0.71%
|
|
|
Neuropharmacology
2 publications, 0.71%
|
|
|
Pharmacology and Therapeutics
2 publications, 0.71%
|
|
|
Medical Journal of Australia
2 publications, 0.71%
|
|
|
Journal of Pediatric Pharmacology and Therapeutics
2 publications, 0.71%
|
|
|
Canadian Journal of Neurological Sciences
2 publications, 0.71%
|
|
|
Journal of Pediatric Neurology
2 publications, 0.71%
|
|
|
5
10
15
20
25
|
Publishers
|
10
20
30
40
50
60
70
80
|
|
|
Elsevier
73 publications, 25.98%
|
|
|
Springer Nature
36 publications, 12.81%
|
|
|
Wiley
26 publications, 9.25%
|
|
|
Cambridge University Press
26 publications, 9.25%
|
|
|
Frontiers Media S.A.
14 publications, 4.98%
|
|
|
MDPI
11 publications, 3.91%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
9 publications, 3.2%
|
|
|
SAGE
9 publications, 3.2%
|
|
|
Taylor & Francis
8 publications, 2.85%
|
|
|
Oxford University Press
5 publications, 1.78%
|
|
|
Mary Ann Liebert
4 publications, 1.42%
|
|
|
Cold Spring Harbor Laboratory
4 publications, 1.42%
|
|
|
Massachusetts Medical Society
3 publications, 1.07%
|
|
|
American Academy of Pediatrics
3 publications, 1.07%
|
|
|
CMA Impact Inc.
3 publications, 1.07%
|
|
|
BMJ
3 publications, 1.07%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
2 publications, 0.71%
|
|
|
Bentham Science Publishers Ltd.
2 publications, 0.71%
|
|
|
American Chemical Society (ACS)
2 publications, 0.71%
|
|
|
Pediatric Pharmacology Advocacy Group, Inc.
2 publications, 0.71%
|
|
|
Hindawi Limited
2 publications, 0.71%
|
|
|
Georg Thieme Verlag KG
2 publications, 0.71%
|
|
|
Emerald
1 publication, 0.36%
|
|
|
F1000 Research
1 publication, 0.36%
|
|
|
Impact Journals
1 publication, 0.36%
|
|
|
American Epilepsy Society
1 publication, 0.36%
|
|
|
Japan Society for Analytical Chemistry
1 publication, 0.36%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.36%
|
|
|
Korean Epilepsy Society
1 publication, 0.36%
|
|
|
10
20
30
40
50
60
70
80
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
281
Total citations:
281
Citations from 2024:
12
(4.27%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Porter B., Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy // Epilepsy and Behavior. 2013. Vol. 29. No. 3. pp. 574-577.
GOST all authors (up to 50)
Copy
Porter B., Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy // Epilepsy and Behavior. 2013. Vol. 29. No. 3. pp. 574-577.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.yebeh.2013.08.037
UR - https://doi.org/10.1016/j.yebeh.2013.08.037
TI - Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
T2 - Epilepsy and Behavior
AU - Porter, Brenda
AU - Jacobson, Catherine
PY - 2013
DA - 2013/12/01
PB - Elsevier
SP - 574-577
IS - 3
VL - 29
PMID - 24237632
SN - 1525-5050
SN - 1525-5069
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2013_Porter,
author = {Brenda Porter and Catherine Jacobson},
title = {Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy},
journal = {Epilepsy and Behavior},
year = {2013},
volume = {29},
publisher = {Elsevier},
month = {dec},
url = {https://doi.org/10.1016/j.yebeh.2013.08.037},
number = {3},
pages = {574--577},
doi = {10.1016/j.yebeh.2013.08.037}
}
Cite this
MLA
Copy
Porter, Brenda, and Catherine Jacobson. “Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.” Epilepsy and Behavior, vol. 29, no. 3, Dec. 2013, pp. 574-577. https://doi.org/10.1016/j.yebeh.2013.08.037.